These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23953216)

  • 1. Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia.
    Boggs DL; Ranganathan M; Sewell RA; Madonick S; D'Souza DC
    Schizophr Res; 2013 Oct; 150(1):323-4. PubMed ID: 23953216
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.
    Barr RS; Culhane MA; Jubelt LE; Mufti RS; Dyer MA; Weiss AP; Deckersbach T; Kelly JF; Freudenreich O; Goff DC; Evins AE
    Neuropsychopharmacology; 2008 Feb; 33(3):480-90. PubMed ID: 17443126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nicotine on cognitive deficits in schizophrenia.
    Harris JG; Kongs S; Allensworth D; Martin L; Tregellas J; Sullivan B; Zerbe G; Freedman R
    Neuropsychopharmacology; 2004 Jul; 29(7):1378-85. PubMed ID: 15138435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?
    Quisenaerts C; Morrens M; Hulstijn W; de Bruijn E; Timmers M; Streffer J; De la Asuncion J; Dumont G; Sabbe B
    Psychopharmacology (Berl); 2014 Feb; 231(3):543-50. PubMed ID: 24022237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia.
    Fisher DJ; Grant B; Smith DM; Borracci G; Labelle A; Knott VJ
    Psychiatry Res; 2012 Apr; 196(2-3):181-7. PubMed ID: 22425471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study.
    Fervaha G; Agid O; Foussias G; Remington G
    Schizophr Res; 2014 Jan; 152(1):317-8. PubMed ID: 24333003
    [No Abstract]   [Full Text] [Related]  

  • 8. Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention.
    Knott VJ; Millar AM; McIntosh JF; Shah DK; Fisher DJ; Blais CM; Ilivitsky V; Horn E
    Biol Psychol; 2011 Sep; 88(1):83-93. PubMed ID: 21742012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.
    Newhouse P; Kellar K; Aisen P; White H; Wesnes K; Coderre E; Pfaff A; Wilkins H; Howard D; Levin ED
    Neurology; 2012 Jan; 78(2):91-101. PubMed ID: 22232050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease.
    Snaedal J; Johannesson T; Jonsson JE; Gylfadottir G
    Dementia; 1996; 7(1):47-52. PubMed ID: 8788082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
    Lemay S; Chouinard S; Blanchet P; Masson H; Soland V; Beuter A; Bédard MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):31-9. PubMed ID: 14687854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nicotine nasal spray on cognitive function in schizophrenia.
    Smith RC; Warner-Cohen J; Matute M; Butler E; Kelly E; Vaidhyanathaswamy S; Khan A
    Neuropsychopharmacology; 2006 Mar; 31(3):637-43. PubMed ID: 16160711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
    Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
    Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.
    D'Souza DC; Ahn K; Bhakta S; Elander J; Singh N; Nadim H; Jatlow P; Suckow RF; Pittman B; Ranganathan M
    Biol Psychiatry; 2012 Nov; 72(9):785-94. PubMed ID: 22717030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
    Turner DC; Clark L; Pomarol-Clotet E; McKenna P; Robbins TW; Sahakian BJ
    Neuropsychopharmacology; 2004 Jul; 29(7):1363-73. PubMed ID: 15085092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits.
    Poltavski DV; Petros T
    Physiol Behav; 2006 Mar; 87(3):614-24. PubMed ID: 16466655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.
    Sacco KA; Creeden C; Reutenauer EL; Vessicchio JC; Weinberger AH; George TP
    Schizophr Res; 2009 Feb; 107(2-3):332-3. PubMed ID: 18995989
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
    Harvey PD; Siu CO; Ogasa M; Loebel A
    Schizophr Res; 2015 Aug; 166(1-3):334-8. PubMed ID: 26117157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual-spatial attention in alcoholics and illicit stimulant abusers: effects of nicotine replacement.
    Ceballos NA; Tivis R; Lawton-Craddock A; Nixon SJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):97-107. PubMed ID: 15610951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.